Publicacións en colaboración con investigadores/as de Hospital Clinic Barcelona (41)

2024

  1. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis

    European urology oncology, Vol. 7, Núm. 4, pp. 860-869

2023

  1. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

    European Urology, Vol. 83, Núm. 5, pp. 393-401

  2. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES

    European Urology, Vol. 84, Núm. 2, pp. 229-241

2022

  1. Advances in Urologic Oncology “OncoUrology Forum Special Edition”: The best of 2020

    Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 214-222

  2. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

    Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282

  3. Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Journal of Clinical Oncology, Vol. 37

  4. Non-metastatic castration-resistant prostate cancer: management recommendations

    Actas Urologicas Espanolas, Vol. 46, Núm. 4, pp. 193-213

  5. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups

    Prostate, Vol. 82, Núm. 13, pp. 1237-1247

2021

  1. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses

    The Journal of urology, Vol. 205, Núm. 5, pp. 1361-1371

  2. Reply by Authors

    The Journal of urology, Vol. 205, Núm. 5, pp. 1371

2020

  1. Advances in urologic oncology “OncoForum”: The best of 2019

    Actas Urologicas Espanolas, Vol. 44, Núm. 9, pp. 586-596

  2. Androgen deprivation therapy in patients with localized disease: Comparison with curative intent treatments and time to castration resistance. Results of the Spanish Prostate Cancer Registry

    Actas Urologicas Espanolas, Vol. 44, Núm. 3, pp. 156-163

  3. Andrología y cáncer de pene. Recomendaciones durante la pandemia COVID-19

    Archivos espanoles de urologia, Vol. 73, Núm. 5, pp. 395-404

  4. Efficacité de l’enzalutamide (ENZA) + traitement par suppression androgénique (TSA) dans le cancer de la prostate hormonosensible métastatique (mHSPC) en fonction de la localisation des métastases : analyses post-hoc de l’étude ARCHES

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 745

  5. Position of Ibero-American Society of Neurourology and UroGynecology (SINUG) on the use of vaginal meshes in pelvic organ prolapse

    Neurourology and Urodynamics, Vol. 39, Núm. 3, pp. 1020-1025

  6. Position of the Ibero-American Society of Neurourology and Urogynecology in relation to the use of synthetic suburethral meshes for the surgical treatment of female stress incontinence

    Neurourology and Urodynamics, Vol. 39, Núm. 1, pp. 464-469

  7. Trasplante renal en época COVID-19 en España

    Archivos espanoles de urologia, Vol. 73, Núm. 5, pp. 447-454

2018

  1. Developments in urologic oncology “OncoForum”: The best of 2017

    Actas Urologicas Espanolas

  2. Safety and efficacy of various strains of bacille Calmette-Guérin in the treatment of bladder tumours in standard clinical practice

    Actas Urologicas Espanolas, Vol. 42, Núm. 4, pp. 238-248

2017

  1. Actividad médico-quirúrgica y estado actual de la formación de los residentes de urología en España: Resultados de una encuesta nacional

    Actas Urologicas Espanolas, Vol. 41, Núm. 6, pp. 391-399